Signed the strategic cooperation framework agreement with Hangzhou AnRun Pharmaceutical;

Strategic Cooperation Framework Agreement

Fufangqinlan Oral Liquid completed a randomized, double-blind, dose-seeking, multicenter Ⅱ phase A clinical trial on the safety and efficacy of acute upper respiratory tract infection in children

Fufangqinlan Oral Liquid

ZBD1042 (HNC042) completed phase I clinical trial and obtained trial summary report; The results showed good safety tolerability and supported further study


ZBD Pharmaceutical“takes scientific and technoligical innovation as its care strategy and quality as the foundation of strategy”Gradually founds the R&D system with five basal research institutes and one management research center. With a range of modulations in reaserch mode including technical imitation, out-sourcing and self-innovate and global registration, corporate business will steady transformed from generics to branded drug or high-end drug and international development will be accelerated. Adhering the reasonable layout of sufficient plan, ZBD Pharmaceutical will devote its entire efforts to be the first-class technological and global innovative Blockbuster enterprises.


Development Platform


News Center


Contact Us


  • Room 611, Building A, World Wealth Center, E Zhongguancun Street, Haidian District, Beijing, China
  • 010-82483501
Your dream partner
Welcome to join us and create business with youJoin us